🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating around the world, with figures suggesting over 82 million new cases per year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs at this time.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to develop it.

“This approval represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Outcomes and Global Access

Based on data released by a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which uses an injection and a pill. The study involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians on the front lines have expressed optimism. Having a single-dose, oral treatment of this kind is described as a "critical tool" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.